Boston Scientific shares slid as softer-than-expected sales momentum raised questions about hospital procedural volumes and medtech demand.

Bausch + Lomb delivered a profitable quarter and lifted its annual outlook, buoyed by surging international demand across its surgical and vision-care segments.

HCA Healthcare reported solid top-line revenue expansion driven by resilient admissions, though elevated labor and clinical expenses squeezed net quarterly profits.

Healthcare equities navigate margin scrutiny, Medicare Advantage reimbursement adjustments, and strategic biopharma acquisitions as investors reposition for sector resilience.